SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (1276)11/1/2004 11:01:09 AM
From: Mike McFarland  Read Replies (1) of 1298
 
What I remember from the call last week:
CEGEs' interest in Ceregene is down to
25%, and it will not figure into the
financials anymore. The offering frees
up somthing on the order of 60M. And
it seems to be pretty clear that CEGE is
working with the FDA on better markers
of clinical efficacy for GVAX. The call
was pretty dull stuff, and I doubt that
anybody who has kept up with the company
would get much out of it.

The finer points of VITAL-1 and VITAL-2 were
lost on me, maybe somebody can explain that?
I will also read this thread. I owned this
for a short time in '99, and bought in last
week after DNDN popped up. Seems to me GVAX
and Provenge are similar, but CEGE is the
better value. It would be fair to say I've
done little DD;-) I'll do more DD as I
decide on a stop loss. No target yet either,
$9 is logical?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News